开盘$887.22
昨收$902.90
当日区间$887.04 – $911.64
成交量1.12M
市值$93.55B
市盈率（TTM）20.0
股息率0.41%
REGN 相关新闻
匹配 Regeneron Pharmaceuticals 或代码 REGN 的头条新闻，按最新排序。
- J.P. Morgan Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $900
- Analysts' Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN), Cytokinetics (CYTK) and Biohaven Ltd. (BHVN)
- HSBC Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $920 正面
- J.P. Morgan Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $900 正面
- Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $917
- Guggenheim Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,030 正面
- Leerink Partners Downgrades Regeneron Pharmaceuticals(REGN.US) to Hold Rating, Announces Target Price $824 负面
- Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $700
- Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $854 负面
- A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $696 to $769
- Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Cuts Target Price to $730 负面
- A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $750 to $960
- Goldman Sachs Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $965 负面
- Guggenheim Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,000 正面
- CCORF Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $875
暂无评论——快来第一个聊聊 REGN。
登录后参与讨论。